Publications from OUS - Inflammatory Bowel Disease Research Group

213 publications found

Publications 2024

1. Andersen V, Pingel J, Søfelt HL, Hikmat Z, Johansson M, Pedersen VS, Bertelsen B, Carlsson A, Lindh M, Svavarsdóttir E, Repsilber D, Joergensen MT, Christensen R, Fejrskov A, Füchtbauer JD, Kjeldsen J, Jensen MD, Aalykke C, Rejler M, Høivik ML, Davidsdottir L, Carlson M, Halfvarson J, Zachariassen HH, Petersen LB et al. (2024)
   Sex and gender in inflammatory bowel disease outcomes and research
   Lancet Gastroenterol Hepatol, 9 (11), 1041-1051
   DOI 10.1016/S2468-1253(24)00159-6, PubMed 39395438
2. Anisdahl K, Lirhus SS, Medhus AW, Moum B, Melberg HO, Høivik ML (2024)
   Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study
   Dig Liver Dis, 56 (9), 1503-1510
   DOI 10.1016/j.dld.2024.02.002, PubMed 38433021
3. Fejrskov A, Füchtbauer JD, Davíðsdóttir LG, Halfvarson J, Høivik ML, Jensen MD, Mortensen JH, Nielsen LN, Rejler M, Repsilber D, Söderholm JD, Aalykke C, Andersen V, Christensen R, Kjeldsen J (2024)
   Novel biomarker profiles to improve individual diagnosis and prognosis in patients with suspected inflammatory bowel disease: protocol for the Nordic inception cohort study (NORDTREAT)
   BMJ Open, 14 (5), e083144
   DOI 10.1136/bmjopen-2023-083144, PubMed 38754881
4. Holten KA, Bernklev T, Opheim R, Olsen BC, Detlie TE, Strande V, Ricanek P, Boyar R, Bengtson MB, Aabrekk TB, Asak Ø, Frigstad SO, Kristensen VA, Hagen M, Henriksen M, Huppertz-Hauss G, Høivik ML, Jelsness-Jørgensen LP (2024)
   Fatigue in patients with inflammatory bowel disease in remission one year after diagnosis (the IBSEN III study)
   J Crohns Colitis (in press)
   DOI 10.1093/ecco-jcc/jjae170, PubMed 39527064
5. Maurud S, Lunde L, Moen A, Opheim R (2024)
   Exploring the foundations of a digital health information service for patients with inflammatory bowel disease: a mixed method study in Gravitate-Health
   BMC Gastroenterol, 24 (1), 184
   DOI 10.1186/s12876-024-03272-1, PubMed 38789953
6. Salihovic S, Nyström N, Mathisen CB, Kruse R, Olbjørn C, Andersen S, Noble AJ, Dorn-Rasmussen M, Bazov I, Perminow G, Opheim R, Detlie TE, Huppertz-Hauss G, Hedin CRH, Carlson M, Öhman L, Magnusson MK, Keita ÅV, Söderholm JD, D'Amato M, Orešič M, Wewer V, Satsangi J, Lindqvist CM, Burisch J et al. (2024)
   Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease
   Nat Commun, 15 (1), 4567
   DOI 10.1038/s41467-024-48763-7, PubMed 38830848
7. Strande V, Høivik ML, Kristensen VA (2024)
   Letter: Critical appraisal of biologic therapy in early ulcerative colitis management-Addressing study limitations and the role of psychological resilience-Authors' reply
   Aliment Pharmacol Ther, 60 (6), 831-832
   DOI 10.1111/apt.18187, PubMed 39072820
8. Strande V, Lund C, Hagen M, Bengtson MB, Cetinkaya RB, Detlie TE, Frigstad SO, Høie O, Medhus AW, Henriksen M, Aass Holten KI, Hovde Ø, Huppertz-Hauss G, Johansen I, Olsen BC, Opheim R, Ricanek P, Torp R, Tønnessen T, Vatn S, Aabrekk TB, Høivik ML, Kristensen VA (2024)
   Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort
   Aliment Pharmacol Ther, 60 (3), 357-368
   DOI 10.1111/apt.18097, PubMed 38837289
9. Wiken TH, Høivik ML, Anisdahl K, Buer L, Warren DJ, Bolstad N, Hagen M, Moum BA, Medhus AW (2024)
   Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study
   Crohns Colitis 360, 6 (1), otae013
   DOI 10.1093/crocol/otae013, PubMed 38544907
10. Zerouga I, Valeur J, Sommer C, Cvancarova Småstuen M, Medhus AW, Lund C, Johansen I, Cetinkaya RB, Bengtson MB, Torp R, Hovde Ø, Huppertz-Hauss G, Detlie TE, Aabrekk TB, Ricanek P, Frigstad SO, Hopstock LA, Opheim R, Kristensen VA, Høivik ML, Hauger Carlsen M, Aas AM (2024)
    Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study
    Scand J Gastroenterol, 59 (6), 652-660
    DOI 10.1080/00365521.2024.2313056, PubMed 38356408

Publications 2023

1. Braadland PR, Bergquist A, Kummen M, Bossen L, Engesæter LK, Reims HM, Björk I, Grzyb K, Abildgaard A, Småstuen MC, Folseraas T, Trøseid M, Ulvik A, Ueland PM, Melum E, Line PD, Høivik ML, Grønbæk H, Karlsen TH, Vesterhus M, Hov JR (2023)
   Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation
   J Hepatol, 79 (4), 955-966
   DOI 10.1016/j.jhep.2023.05.038, PubMed 37328069
2. Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, Kaplan GG, Duricova D, Greenberg D, Melberg HO, Watanabe M, Ahn HS, Targownik L, Pittet VEH, Annese V, Park KT, Katsanos KH, Høivik ML, Krznaric Z, Chaparro M, Loftus EV, Lakatos PL, Gisbert JP, Bemelman W, Moum B et al. (2023)
   The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
   Lancet Gastroenterol Hepatol, 8 (5), 458-492
   DOI 10.1016/S2468-1253(23)00003-1, PubMed 36871566
3. Ecklu-Mensah G, Choo-Kang C, Maseng MG, Donato S, Bovet P, Viswanathan B, Bedu-Addo K, Plange-Rhule J, Oti Boateng P, Forrester TE, Williams M, Lambert EV, Rae D, Sinyanya N, Luke A, Layden BT, O'Keefe S, Gilbert JA, Dugas LR (2023)
   Gut microbiota and fecal short chain fatty acids differ with adiposity and country of origin: the METS-microbiome study
   Nat Commun, 14 (1), 5160
   DOI 10.1038/s41467-023-40874-x, PubMed 37620311
4. Evensen H, Sandstad O, Larssen L, Hagen M, Kristensen VA, Søvik TT, Schulz A, Hauge T, Medhus AW (2023)
   Intraoperative distensibility measurement in POEM for achalasia: impact on patient outcome and associations with other outcome variables at 1-year follow-up
   Surg Endosc, 37 (12), 9283-9290
   DOI 10.1007/s00464-023-10494-z, PubMed 37880446
5. Follin-Arbelet B, Cvancarova Småstuen M, Hovde Ø, Jelsness-Jørgensen LP, Moum B (2023)
   Mortality in Patients with Inflammatory Bowel Disease: Results from 30 Years of Follow-up in a Norwegian Inception Cohort (the IBSEN study)
   J Crohns Colitis, 17 (4), 497-503
   DOI 10.1093/ecco-jcc/jjac156, PubMed 36239614
6. Follin-Arbelet B, Cvancarova Småstuen M, Hovde Ø, Jelsness-Jørgensen LP, Moum B (2023)
   Risk of Cancer in Patients With Crohn's Disease 30 Years After Diagnosis (the IBSEN Study)
   Crohns Colitis 360, 5 (4), otad057
   DOI 10.1093/crocol/otad057, PubMed 37886706
7. Follin-Arbelet B, Småstuen MC, Hovde Ø, Jelsness-Jørgensen LP, Moum B (2023)
   Incidence of cancer in patients with ulcerative colitis 30 years after diagnosis (the IBSEN study)
   Scand J Gastroenterol, 58 (11), 1264-1270
   DOI 10.1080/00365521.2023.2223709, PubMed 37337889
8. Fossmark R, Lirhus SS, Høivik ML (2023)
   The impact of proton pump inhibitors on the course of ulcerative colitis: a cohort study of over 10,000 newly diagnosed patients in Norway
   Scand J Gastroenterol, 59 (1), 46-51
   DOI 10.1080/00365521.2023.2255710, PubMed 37681998
9. Holten KIA, Bernklev T, Opheim R, Johansen I, Olsen BC, Lund C, Strande V, Medhus AW, Perminow G, Bengtson MB, Cetinkaya RB, Vatn S, Frigstad SO, Aabrekk TB, Detlie TE, Hovde Ø, Kristensen VA, Småstuen MC, Henriksen M, Huppertz-Hauss G, Høivik ML, Jelsness-Jørgensen LP (2023)
   Fatigue in Patients with Newly Diagnosed Inflammatory Bowel Disease: Results from a Prospective Inception Cohort, the IBSEN III Study
   J Crohns Colitis, 17 (11), 1781-1790
   DOI 10.1093/ecco-jcc/jjad094, PubMed 37279652
10. Horrigan JM, Louis E, Spinelli A, Travis S, Moum B, Salwen-Deremer J, Halfvarson J, Panaccione R, Dubinsky MC, Munkholm P, Siegel CA (2023)
    The Real-World Global Use of Patient-Reported Outcomes for the Care of Patients With Inflammatory Bowel Disease
    Crohns Colitis 360, 5 (2), otad006
    DOI 10.1093/crocol/otad006, PubMed 36937140
11. Johansen I, Småstuen MC, Løkkeberg ST, Kristensen VA, Høivik ML, Lund C, Olsen B, Strande V, Huppertz-Hauss G, Aabrekk TB, Bengtson MB, Ricanek P, Detlie TE, Frigstad SO, Jelsness-Jørgensen LP, Opheim R (2023)
    Symptoms and symptom clusters in patients newly diagnosed with inflammatory bowel disease: results from the IBSEN III Study
    BMC Gastroenterol, 23 (1), 255
    DOI 10.1186/s12876-023-02889-y, PubMed 37501083
12. Jørgensen KK, Høivik ML, Chopra A, Benth JŠ, Ricanek P, Moum PB, Jyssum I, Bolstad N, Warren DJ, Vaage PJT, Munthe PLA, Lundin PKEA, Anisdahl K, Syversen SW, Goll GL, Lund-Johansen F, Medhus AW, Jahnsen PJ (2023)
    Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type
    Scand J Gastroenterol, 58 (8), 874-882
    DOI 10.1080/00365521.2023.2177884, PubMed 36788656
13. Lindemann K, Heimisdottir Danbolt S, Ramberg L, Eyjólfsdóttir B, Wang YY, Heli-Haugestøl AG, Walcott SL, Mjåland O, Navestad GA, Hermanrud S, Juul-Hansen KE, Bragstad LK, Opheim R, Kleppe A, Kongsgaard U (2023)
    Patient-reported nausea after implementation of an enhanced recovery after surgery protocol for gynae-oncology patients
    Int J Gynecol Cancer, 33 (8), 1287-1294
    DOI 10.1136/ijgc-2023-004356, PubMed 37451689
14. Olsen BC, Opheim R, Kristensen VA, Høivik ML, Lund C, Aabrekk TB, Johansen I, Holten K, Strande V, Bengtson MB, Ricanek P, Detlie TE, Bernklev T, Jelsness-Jørgensen LP, Huppertz-Hauss G (2023)
    Health-related quality of life in patients with newly diagnosed inflammatory bowel disease: an observational prospective cohort study (IBSEN III)
    Qual Life Res, 32 (10), 2951-2964
    DOI 10.1007/s11136-023-03435-9, PubMed 37219727
15. Svendsen EJ, Opheim R, Hermansen BE, Hardeland C (2023)
    Ad hoc digital communication and assessment during clinical placements in nursing education; a qualitative research study of students', clinical instructors', and teachers' experiences
    PLoS One, 18 (7), e0287438
    DOI 10.1371/journal.pone.0287438, PubMed 37478099
16. Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson K et al. (2023)
    Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
    NPJ Vaccines, 8 (1), 4
    DOI 10.1038/s41541-023-00600-6, PubMed 36697432
17. Wiken TH, Høivik ML, Buer L, Warren DJ, Bolstad N, Moum BA, Anisdahl K, Småstuen MC, Medhus AW (2023)
    Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
    Scand J Gastroenterol, 58 (8), 863-873
    DOI 10.1080/00365521.2023.2176252, PubMed 36799155

Publications 2022

1. Evensen H, Hjermstad MJ, Cvancarova M, Kristensen V, Larssen L, Skattum J, Hauge T, Sandstad O, Medhus AW (2022)
   Quality of life in patients with achalasia: Associations with Eckardt score and objective treatment outcomes after peroral endoscopic myotomy
   Endosc Int Open, 10 (12), E1570-E1576
   DOI 10.1055/a-1968-7682, PubMed 36531682
2. Jelsness-Jørgensen LP, Moum B, Grimstad T, Jahnsen J, Hovde Ø, Frigstad SO, Bernklev T (2022)
   The multidimensional fatigue inventory (MFI-20): psychometrical testing in a Norwegian sample of inflammatory bowel disease (IBD) patients
   Scand J Gastroenterol, 1-7 (in press)
   DOI 10.1080/00365521.2022.2029939, PubMed 35076321
3. Lindgren S, Hjortswang H, Moum B, Vasko P, H Lund L (2022)
   [Iron deficiency in patients with acute and chronic heart failure - a simple algoritm]
   Lakartidningen, 119
   PubMed 36149233
4. Opheim R, Moum KM, Småstuen MC, Moum B (2022)
   The impact of restrictions on psychological outcomes in patients with inflammatory bowel disease on biological treatment during the coronavirus pandemic in Norway
   Qual Life Res, 32 (3), 691-699
   DOI 10.1007/s11136-022-03254-4, PubMed 36125603
5. Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson K et al. (2022)
   Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
   NPJ Vaccines, 7 (1), 174
   DOI 10.1038/s41541-022-00586-7, PubMed 36585405
6. Zhao M, Lirhus S, Lördal M, Langholz E, Knudsen T, Voutilainen M, Høivik ML, Moum B, Anisdahl K, Saebø B, Haiko P, Malmgren C, Coskun M, Melberg HO, Burisch J (2022)
   Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway
   Aliment Pharmacol Ther, 56 (6), 989-1006
   DOI 10.1111/apt.17145, PubMed 35902223

Publications 2021

1. Anisdahl K, Svatun Lirhus S, Medhus AW, Moum B, Melberg HO, Høivik ML (2021)
   First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study
   Scand J Gastroenterol, 56 (10), 1163-1168
   DOI 10.1080/00365521.2021.1955147, PubMed 34320885
2. Evensen H, Småstuen MC, Schulz A, Kristensen V, Larssen L, Skattum J, Sandstad O, Hauge T, Medhus AW (2021)
   One year comprehensive prospective follow-up of achalasia patients after peroral endoscopic myotomy
   Ann Med, 53 (1), 2225-2233
   DOI 10.1080/07853890.2021.2005253, PubMed 34806501
3. Kristensen VA, Opheim R, Perminow G, Huppertz-Hauss G, Detlie TE, Lund C, Andersen S, Olsen BC, Johansen I, Medhus AW, Vatn S, Brackmann S, Olbjørn C, Rove J, Henriksen M, Løvlund EE, Bengtson MB, Aabrekk TB, Tønnessen T, Vikskjold FB, Yassin H, Frigstad SO, Hasund A, Høie O, Schmidt K et al. (2021)
   Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway
   Scand J Gastroenterol, 56 (8), 899-905
   DOI 10.1080/00365521.2021.1922746, PubMed 34154494
4. Lirhus SS, Høivik ML, Moum B, Anisdahl K, Melberg HO (2021)
   Incidence and Prevalence of Inflammatory Bowel Disease in Norway and the Impact of Different Case Definitions: A Nationwide Registry Study
   Clin Epidemiol, 13, 287-294
   DOI 10.2147/CLEP.S303797, PubMed 33935519
5. Monstad IL, Solberg IC, Cvancarova M, Hovde O, Henriksen M, Huppertz-Hauss G, Gunther E, Moum BA, Stray N, Vatn M, Hoie O, Jahnsen J (2021)
   Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study
   J Crohns Colitis, 15 (6), 969-979
   DOI 10.1093/ecco-jcc/jjaa232, PubMed 33367569
6. Moum KM, Moum B, Opheim R (2021)
   Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic
   Scand J Gastroenterol, 56 (5), 545-551
   DOI 10.1080/00365521.2021.1901308, PubMed 33771086
7. Sousa P, Ministro P, Armuzzi A, Dignass A, Høivik ML, Barreiro-de Acosta M, Vavricka S, Saad-Hossne R, Kotze PG, Peyrin-Biroulet L, Magro F (2021)
   Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease
   Dig Liver Dis, 53 (12), 1571-1579
   DOI 10.1016/j.dld.2021.05.038, PubMed 34187768

Publications 2020

1. Hedin CRH, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A, Gerussi A, Saffioti F, Thorburn D, Nilsson E, Larsson G, Moum BA, van Munster KN, Ponsioen CY, Levy C, Nogueira NF, Bowlus CL, Gotlieb N, Shibolet O, Lynch KD, Chapman RW, Rupp C, Vesterhus M, Jørgensen KK, Rorsman F et al. (2020)
   Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
   Clin Gastroenterol Hepatol, 18 (10), 2295-2304.e2
   DOI 10.1016/j.cgh.2020.02.014, PubMed 32068151
2. Jørgensen KK, Goll GL, Sexton J, Bolstad N, Olsen IC, Asak Ø, Berset IP, Blomgren IM, Dvergsnes K, Florholmen J, Frigstad SO, Henriksen M, Hagfors J, Huppertz-Hauss G, Haavardsholm EA, Klaasen RA, Moum B, Noraberg G, Prestegård U, Rydning JH, Sagatun L, Seeberg KA, Torp R, Vold C, Warren DJ et al. (2020)
   Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
   BioDrugs, 34 (5), 681-694
   DOI 10.1007/s40259-020-00438-7, PubMed 32965617
3. Klepp P, Brackmann S, Cvancarova M, Hoivik ML, Hovde Ø, Henriksen M, Huppertz-Hauss G, Bernklev T, Hoie O, Kempski-Monstad I, Solberg IC, Stray N, Jahnsen J, Vatn MH, Moum B (2020)
   Risk of colorectal cancer in a population-based study 20 years after diagnosis of ulcerative colitis: results from the IBSEN study
   BMJ Open Gastroenterol, 7 (1), e000361
   DOI 10.1136/bmjgast-2019-000361, PubMed 32337058
4. Kravdal Ø, Magnus P, Moum B, Høivik ML (2020)
   Association of Childbearing With a Short-Term Reduced Risk of Crohn Disease in Mothers
   Am J Epidemiol, 189 (4), 294-304
   DOI 10.1093/aje/kwz285, PubMed 31907543
5. Kristensen VA, Cvancarova M, Høivik ML, Moum B, Vatn MH (2020)
   Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study
   Scand J Gastroenterol, 55 (4), 436-441
   DOI 10.1080/00365521.2020.1745879, PubMed 32252542
6. Kummen M, Thingholm LB, Rühlemann MC, Holm K, Hansen SH, Moitinho-Silva L, Liwinski T, Zenouzi R, Storm-Larsen C, Midttun Ø, McCann A, Ueland PM, Høivik ML, Vesterhus M, Trøseid M, Laudes M, Lieb W, Karlsen TH, Bang C, Schramm C, Franke A, Hov JR (2020)
   Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis
   Gastroenterology, 160 (5), 1784-1798.e0
   DOI 10.1053/j.gastro.2020.12.058, PubMed 33387530
7. Opheim R, Moum B, Grimstad BT, Jahnsen J, Prytz Berset I, Hovde Ø, Huppertz-Hauss G, Bernklev T, Jelsness-Jørgensen LP (2020)
   Self-esteem in patients with inflammatory bowel disease
   Qual Life Res, 29 (7), 1839-1846
   DOI 10.1007/s11136-020-02467-9, PubMed 32144613
8. Ossum AM, Palm Ø, Cvancarova M, Bernklev T, Jahnsen J, Moum B, Høivik ML, IBSEN Study Group (2020)
   The Impact of Spondyloarthritis and Joint Symptoms on Health-Related Quality of Life and Fatigue in IBD Patients. Results From a Population-Based Inception Cohort (20-Year Follow-up in the Ibsen Study)
   Inflamm Bowel Dis, 26 (1), 114-124
   DOI 10.1093/ibd/izz105, PubMed 31127829
9. Vesterhus M, Nielsen MJ, Hov JR, Saffioti F, Manon-Jensen T, Leeming DJ, Moum B, Boberg KM, Pinzani M, Karlsen TH, Karsdal MA, Thorburn D (2020)
   Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease
   JHEP Rep, 3 (1), 100178
   DOI 10.1016/j.jhepr.2020.100178, PubMed 33225252

Publications 2019

1. Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, Høivik ML (2019)
   Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort
   Scand J Gastroenterol, 54 (1), 41-48
   DOI 10.1080/00365521.2018.1548646, PubMed 30650312
2. Detlie TE, Lindstrøm JC, Jahnsen ME, Finnes E, Zoller H, Moum B, Jahnsen J (2019)
   Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside
   Aliment Pharmacol Ther, 50 (4), 397-406
   DOI 10.1111/apt.15386, PubMed 31264261
3. Evensen H, Kristensen V, Larssen L, Sandstad O, Hauge T, Medhus AW (2019)
   Outcome of peroral endoscopic myotomy (POEM) in treatment-naive patients. A systematic review
   Scand J Gastroenterol, 54 (1), 1-7
   DOI 10.1080/00365521.2018.1549271, PubMed 30650313
4. Frigstad SO, Høivik ML, Jahnsen J, Cvancarova M, Grimstad T, Berset IP, Huppertz-Hauss G, Hovde Ø, Bernklev T, Moum B, Jelsness-Jørgensen LP (2019)
   Pain Severity and Vitamin D Deficiency in IBD Patients
   Nutrients, 12 (1)
   DOI 10.3390/nu12010026, PubMed 31877637
5. Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KEA, Tveit KS, Lorentzen M, Berset IP, Fevang BTS, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G et al. (2019)
   Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
   J Intern Med, 285 (6), 653-669
   DOI 10.1111/joim.12880, PubMed 30762274
6. Kristensen VA, Valeur J, Brackmann S, Jahnsen J, Brunborg C, Tveito K (2019)
   Attention deficit and hyperactivity disorder symptoms respond to gluten-free diet in patients with coeliac disease
   Scand J Gastroenterol, 54 (5), 571-576
   DOI 10.1080/00365521.2019.1608467, PubMed 31050907
7. Torres J, Ellul P, Langhorst J, Mikocka-Walus A, Barreiro-de Acosta M, Basnayake C, Ding NJS, Gilardi D, Katsanos K, Moser G, Opheim R, Palmela C, Pellino G, Van der Marel S, Vavricka SR (2019)
   European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease
   J Crohns Colitis, 13 (6), 673-685e
   DOI 10.1093/ecco-jcc/jjz051, PubMed 30820529

Publications 2018

1. Buer LCT, Høivik ML, Warren DJ, Medhus AW, Moum BA (2018)
   Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
   Inflamm Bowel Dis, 24 (5), 997-1004
   DOI 10.1093/ibd/izx110, PubMed 29668901
2. Dhillon AK, Kummen M, Trøseid M, Åkra S, Liaskou E, Moum B, Vesterhus M, Karlsen TH, Seljeflot I, Hov JR (2018)
   Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis
   Liver Int, 39 (2), 371-381
   DOI 10.1111/liv.13979, PubMed 30269440
3. Engebretsen KV, Blom-Høgestøl IK, Hewitt S, Risstad H, Moum B, Kristinsson JA, Mala T (2018)
   Anemia following Roux-en-Y gastric bypass for morbid obesity; a 5-year follow-up study
   Scand J Gastroenterol, 53 (8), 917-922
   DOI 10.1080/00365521.2018.1489892, PubMed 30231804
4. Frigstad SO, Høivik ML, Jahnsen J, Cvancarova M, Grimstad T, Berset IP, Huppertz-Hauss G, Hovde Ø, Bernklev T, Moum B, Jelsness-Jørgensen LP (2018)
   Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease patients
   World J Gastroenterol, 24 (29), 3293-3301
   DOI 10.3748/wjg.v24.i29.3293, PubMed 30090009
5. Henriksen M, Høivik ML, Jelsness-Jørgensen LP, Moum B, IBSEN Study Group (2018)
   Irritable Bowel-like Symptoms in Ulcerative Colitis are as Common in Patients in Deep Remission as in Inflammation: Results From a Population-based Study [the IBSEN Study]
   J Crohns Colitis, 12 (4), 389-393
   DOI 10.1093/ecco-jcc/jjx152, PubMed 29186372
6. Høivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, Medhus AW (2018)
   Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population
   Scand J Gastroenterol, 53 (6), 692-699
   DOI 10.1080/00365521.2018.1463391, PubMed 29852793
7. Klepp P, Kisiel JB, Småstuen MC, Røseth A, Andersen SN, Vatn MH, Ahlquist DA, Moum BA, Brackmann S (2018)
   Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study
   Scand J Gastroenterol, 53 (3), 273-278
   DOI 10.1080/00365521.2018.1424935, PubMed 29313389
8. Lirhus SS, Høivik ML, Moum B, Melberg HO (2018)
   Regional differences in anti-TNF-α therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study
   Scand J Gastroenterol, 53 (8), 952-957
   DOI 10.1080/00365521.2018.1495258, PubMed 30205699
9. Ossum AM, Palm Ø, Cvancarova M, Solberg IC, Vatn M, Moum B, Høivik ML, IBSEN study group (2018)
   Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study
   Scand J Gastroenterol, 53 (10-11), 1250-1256
   DOI 10.1080/00365521.2018.1518482, PubMed 30353756
10. Ossum AM, Palm Ø, Lunder AK, Cvancarova M, Banitalebi H, Negård A, Høie O, Henriksen M, Moum BA, Høivik ML, IBSEN Study Group (2018)
    Ankylosing Spondylitis and Axial Spondyloarthritis in Patients With Long-term Inflammatory Bowel Disease: Results From 20 Years of Follow-up in the IBSEN Study
    J Crohns Colitis, 12 (1), 96-104
    DOI 10.1093/ecco-jcc/jjx126, PubMed 28961700
11. Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, Nielsen KR, Brassard P, Vutcovici M, Bitton A, Bernstein CN, Leddin D, Tamim H, Stefansson T, Loftus EV, Moum B, Tang W, Ng SC, Gearry R, Sincic B, Bell S, Sands BE, Lakatos PL, Végh Z, Ott C et al. (2018)
    Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries
    Gastroenterology, 155 (4), 1079-1089.e3
    DOI 10.1053/j.gastro.2018.06.043, PubMed 29958857

Publications 2017

1. Buer L, Høivik ML, Medhus AW, Moum B (2017)
   Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
   Dig Dis, 35 (1-2), 74-82
   DOI 10.1159/000449087, PubMed 28147370
2. Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML (2017)
   Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study
   J Crohns Colitis, 11 (3), 297-304
   DOI 10.1093/ecco-jcc/jjw166, PubMed 27660339
3. Burisch J, Vegh Z, Katsanos KH, Christodoulou DK, Lazar D, Goldis A, O'Morain C, Fernandez A, Pereira S, Myers S, Sebastian S, Pedersen N, Olse J, Rubek Nielsen K, Schwartz D, Odes S, Almer S, Halfvarson J, Turk N, Cukovic-Cavka S, Nikulina I, Belousova E, Duricova D, Bortlik M, Shonová O et al. (2017)
   Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort-An ECCO-EpiCom Study
   J Crohns Colitis, 11 (10), 1213-1222
   DOI 10.1093/ecco-jcc/jjx077, PubMed 28575481
4. Hovde Ø, Høivik ML, Henriksen M, Solberg IC, Småstuen MC, Moum BA (2017)
   Corrigendum: Malignancies in Patients with Inflammatory Bowel Disease (IBD): Results from 20 Years of Follow-up in the IBSEN (Inflammatory Bowel South-Eastern Norway) Study
   J Crohns Colitis, 11 (12), 1511
   DOI 10.1093/ecco-jcc/jjw218, PubMed 28039308
5. Hovde Ø, Høivik ML, Henriksen M, Solberg IC, Småstuen MC, Moum BA (2017)
   Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study
   J Crohns Colitis, 11 (5), 571-577
   DOI 10.1093/ecco-jcc/jjw193, PubMed 28453756
6. Kristensen V, Røseth A, Ahmad T, Skar V, Moum B (2017)
   Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis
   Gastroenterol Res Pract, 2017, 2098293
   DOI 10.1155/2017/2098293, PubMed 29225617
7. Lerdal A, Opheim R, Gay CL, Moum B, Fagermoen MS, Kottorp A (2017)
   Psychometric limitations of the 13-item Sense of Coherence Scale assessed by Rasch analysis
   BMC Psychol, 5 (1), 18
   DOI 10.1186/s40359-017-0187-y, PubMed 28595651
8. Tronstad RR, Kummen M, Holm K, von Volkmann HL, Anmarkrud JA, Høivik ML, Moum B, Gilja OH, Hausken T, Baines J, Karlsen TH, Fiskerstrand T, Hov JR (2017)
   Guanylate Cyclase C Activation Shapes the Intestinal Microbiota in Patients with Familial Diarrhea and Increased Susceptibility for Crohn's Disease
   Inflamm Bowel Dis, 23 (10), 1752-1761
   DOI 10.1097/MIB.0000000000001264, PubMed 28902124
9. Vesterhus M, Holm A, Hov JR, Nygård S, Schrumpf E, Melum E, Thorbjørnsen LW, Paulsen V, Lundin K, Dale I, Gilja OH, Zweers SJLB, Vatn M, Schaap FG, Jansen PLM, Ueland T, Røsjø H, Moum B, Ponsioen CY, Boberg KM, Färkkilä M, Karlsen TH, Lund-Johansen F (2017)
   Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis
   J Hepatol, 66 (6), 1214-1222
   DOI 10.1016/j.jhep.2017.01.019, PubMed 28161472

Publications 2016

1. Follin-Arbelet B, Moum B (2016)
   Fluoride: a risk factor for inflammatory bowel disease?
   Scand J Gastroenterol, 51 (9), 1019-24
   DOI 10.1080/00365521.2016.1177855, PubMed 27199224
2. Frigstad SO, Høivik M, Jahnsen J, Dahl SR, Cvancarova M, Grimstad T, Berset IP, Huppertz-Hauss G, Hovde Ø, Torp R, Bernklev T, Moum B, Jelsness-Jørgensen LP (2016)
   Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population
   Scand J Gastroenterol, 52 (1), 100-106
   DOI 10.1080/00365521.2016.1233577, PubMed 27603182
3. Hovde Ø, Småstuen MC, Høivik ML, Bernklev T, Huppertz-Hauss G, Høie O, Jahnsen J, Stray N, Henriksen M, Solberg IC, Moum BA (2016)
   Mortality and Causes of Death in Ulcerative Colitis: Results from 20 Years of Follow-up in the IBSEN Study
   Inflamm Bowel Dis, 22 (1), 141-5
   DOI 10.1097/MIB.0000000000000582, PubMed 26355464
4. Huppertz-Hauss G, Høivik ML, Jelsness-Jørgensen LP, Opheim R, Henriksen M, Høie O, Hovde Ø, Kempski-Monstad I, Solberg IC, Jahnsen J, Hoff G, Moum B, Bernklev T (2016)
   Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study
   Scand J Gastroenterol, 52 (3), 351-358
   DOI 10.1080/00365521.2016.1256425, PubMed 27852169
5. Huppertz-Hauss G, Lie Høivik M, Jelsness-Jørgensen LP, Henriksen M, Høie O, Jahnsen J, Hoff G, Moum B, Bernklev T (2016)
   Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis: Results from the IBSEN Study
   Inflamm Bowel Dis, 22 (7), 1679-87
   DOI 10.1097/MIB.0000000000000806, PubMed 27206016
6. Huppertz-Hauss G, Aas E, Lie Høivik M, Langholz E, Odes S, Småstuen M, Stockbrugger R, Hoff G, Moum B, Bernklev T (2016)
   Comparison of the Multiattribute Utility Instruments EQ-5D and SF-6D in a Europe-Wide Population-Based Cohort of Patients with Inflammatory Bowel Disease 10 Years after Diagnosis
   Gastroenterol Res Pract, 2016, 5023973
   DOI 10.1155/2016/5023973, PubMed 27630711
7. Jelsness-Jørgensen LP, Frigstad SO, Moum B, Grimstad T, Opheim R, Jahnsen J, Bernklev T (2016)
   Pain may be an important factor to consider in inflammatory bowel disease patients troubled by fatigue
   United European Gastroenterol J, 5 (5), 687-693
   DOI 10.1177/2050640616674654, PubMed 28815032
8. Jelsness-Jørgensen LP, Moum B, Grimstad T, Jahnsen J, Opheim R, Prytz Berset I, Hovde Ø, Torp R, Frigstad SO, Huppertz-Hauss G, Bernklev T (2016)
   Validity, Reliability, and Responsiveness of the Brief Pain Inventory in Inflammatory Bowel Disease
   Can J Gastroenterol Hepatol, 2016, 5624261
   DOI 10.1155/2016/5624261, PubMed 27446848
9. Jørgensen SF, Trøseid M, Kummen M, Anmarkrud JA, Michelsen AE, Osnes LT, Holm K, Høivik ML, Rashidi A, Dahl CP, Vesterhus M, Halvorsen B, Mollnes TE, Berge RK, Moum B, Lundin KE, Fevang B, Ueland T, Karlsen TH, Aukrust P, Hov JR (2016)
   Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation
   Mucosal Immunol, 9 (6), 1455-1465
   DOI 10.1038/mi.2016.18, PubMed 26982597
10. Kristensen V, Lauritzen T, Jelsness-Jørgensen LP, Frigstad SO, Corwin C, Moum B (2016)
    Patient-performed extraction of faecal calprotectin
    Clin Chem Lab Med, 54 (8), 1357-63
    DOI 10.1515/cclm-2015-1037, PubMed 26812797
11. Kummen M, Holm K, Anmarkrud JA, Nygård S, Vesterhus M, Høivik ML, Trøseid M, Marschall HU, Schrumpf E, Moum B, Røsjø H, Aukrust P, Karlsen TH, Hov JR (2016)
    The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls
    Gut, 66 (4), 611-619
    DOI 10.1136/gutjnl-2015-310500, PubMed 26887816
12. Kummen M, Vesterhus M, Trøseid M, Moum B, Svardal A, Boberg KM, Aukrust P, Karlsen TH, Berge RK, Hov JR (2016)
    Elevated trimethylamine-N-oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function
    United European Gastroenterol J, 5 (4), 532-541
    DOI 10.1177/2050640616663453, PubMed 28588885
13. Lunder AK, Hov JR, Borthne A, Gleditsch J, Johannesen G, Tveit K, Viktil E, Henriksen M, Hovde Ø, Huppertz-Hauss G, Høie O, Høivik ML, Monstad I, Solberg IC, Jahnsen J, Karlsen TH, Moum B, Vatn M, Negård A (2016)
    Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease
    Gastroenterology, 151 (4), 660-669.e4
    DOI 10.1053/j.gastro.2016.06.021, PubMed 27342213
14. Opheim R, Lie Høivik M, Bernklev T, Jelsness-Jørgensen LP, Moum B (2016)
    The Use of Complementary and Alternative Medicine among Patients with Inflammatory Bowel Disease Is Associated with Reduced Health-Related Quality of Life
    Gastroenterol Res Pract, 2016, 6453657
    DOI 10.1155/2016/6453657, PubMed 28003821
15. Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DPB, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S et al. (2016)
    Development of an index to define overall disease severity in IBD
    Gut, 67 (2), 244-254
    DOI 10.1136/gutjnl-2016-312648, PubMed 27780886

Publications 2015

1. Huppertz-Hauss G, Høivik ML, Langholz E, Odes S, Småstuen M, Stockbrugger R, Hoff G, Moum B, Bernklev T (2015)
   Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis
   Inflamm Bowel Dis, 21 (2), 337-44
   DOI 10.1097/MIB.0000000000000272, PubMed 25569735
2. Jelsness-Jørgensen LP, Bernklev T, Hovde Ø, Prytz Berset I, Huppertz-Hauss G, Moum B, Lie Høivik M (2015)
   Patients' perceptions of quality of care and follow-up in inflammatory bowel disease
   Scand J Gastroenterol, 51 (4), 434-41
   DOI 10.3109/00365521.2015.1102319, PubMed 26635189
3. Kristensen V, Klepp P, Cvancarova M, Røseth A, Skar V, Moum B (2015)
   Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin
   J Crohns Colitis, 9 (2), 164-9
   DOI 10.1093/ecco-jcc/jju015, PubMed 25518057
4. Kristensen V, Lauritzen T, Jelsness-JØrgensen LP, Moum B (2015)
   Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods
   Scand J Clin Lab Invest, 75 (5), 355-61
   DOI 10.3109/00365513.2015.1030765, PubMed 25856663
5. Kristensen V, Malmstrøm GH, Skar V, Røseth A, Moum B (2015)
   Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure
   Scand J Gastroenterol, 51 (5), 548-55
   DOI 10.3109/00365521.2015.1117650, PubMed 26634305
6. Kristensen V, Moum B (2015)
   Correspondence: fecal calprotectin and cut-off levels in inflammatory bowel disease
   Scand J Gastroenterol, 50 (9), 1183-4
   DOI 10.3109/00365521.2015.1025830, PubMed 25772406
7. Moum B (2015)
   Challenges in the care of IBD in patients of all ages
   Tidsskr. Nor. Laegeforen., 135 (2), 157
   DOI 10.4045/tidsskr.14.1267
8. Solberg IC, Høivik ML, Cvancarova M, Moum B, IBSEN Study Group (2015)
   Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study)
   Scand J Gastroenterol, 50 (12), 1456-62
   DOI 10.3109/00365521.2015.1064991, PubMed 26139389
9. Vesterhus M, Hov JR, Holm A, Schrumpf E, Nygård S, Godang K, Andersen IM, Naess S, Thorburn D, Saffioti F, Vatn M, Gilja OH, Lund-Johansen F, Syversveen T, Brabrand K, Parés A, Ponsioen CY, Pinzani M, Färkkilä M, Moum B, Ueland T, Røsjø H, Rosenberg W, Boberg KM, Karlsen TH (2015)
   Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis
   Hepatology, 62 (1), 188-97
   DOI 10.1002/hep.27825, PubMed 25833813

Publications 2014

1. Filmann N, Rey J, Schneeweiss S, Ardizzone S, Bager P, Bergamaschi G, Koutroubakis I, Lindgren S, Morena Fde L, Moum B, Vavricka SR, Schröder O, Herrmann E, Blumenstein I (2014)
   Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis
   Inflamm Bowel Dis, 20 (5), 936-45
   DOI 10.1097/01.MIB.0000442728.74340.fd, PubMed 24572205
2. Gomollón F, Chowers Y, Danese S, Dignass A, Haagen Nielsen O, Lakatos PL, Lees CW, Lindgren S, Lukas M, Mantzaris GJ, Michetti P, Moum B, Peyrin-Biroulet L, Toruner M, van der Woude J, Weiss G, Stoevelaar H, Reinisch W (2014)
   Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines
   Aliment Pharmacol Ther, 39 (7), 743-4
   DOI 10.1111/apt.12648, PubMed 24588280
3. Isene R, Bernklev T, Høie O, Langholz E, Tsianos E, Stockbrügger R, Odes S, Småstuen M, Moum B, EC-IBD Study Group (2014)
   Thromboembolism in inflammatory bowel disease: results from a prospective, population-based European inception cohort
   Scand J Gastroenterol, 49 (7), 820-5
   DOI 10.3109/00365521.2014.910545, PubMed 24754745
4. Isene R, Bernklev T, Høie O, Munkholm P, Tsianos E, Stockbrügger R, Odes S, Palm Ø, Småstuen M, Moum B, EC-IBD Study Group (2014)
   Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort
   Scand J Gastroenterol, 50 (3), 300-5
   DOI 10.3109/00365521.2014.991752, PubMed 25535653
5. Jelsness-Jørgensen LP, Bernklev T, Moum B (2014)
   Coexisting irritable bowel-like symptoms in inflammatory bowel disease in remission is associated with impaired social functioning and increased bodily pain
   Gastroenterol Nurs, 37 (4), 280-7
   DOI 10.1097/SGA.0000000000000055, PubMed 25078042
6. Larsson G, Shenoy KT, Ramasubramanian R, Thayumanavan L, Balakumaran LK, Bjune GA, Moum BA (2014)
   Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India
   United European Gastroenterol J, 2 (5), 397-405
   DOI 10.1177/2050640614546947, PubMed 25360318
7. Larsson G, Shenoy KT, Ramasubramanian R, Thayumanavan L, Balakumaran LK, Bjune GA, Moum BA (2014)
   High faecal calprotectin levels in intestinal tuberculosis are associated with granulomas in intestinal biopsies
   Infect Dis (Lond), 47 (3), 137-43
   DOI 10.3109/00365548.2014.974206, PubMed 25522183
8. Moum B, Hovde Ø, Høivik ML (2014)
   What have we learnt about the role of the environment and natural course of IBD in the new millennium? 20-year follow-up of the IBSEN cohort
   Dig Dis, 32 Suppl 1, 2-9
   DOI 10.1159/000367818, PubMed 25531347
9. Opheim R, Fagermoen MS, Jelsness-Jørgensen LP, Bernklev T, Moum B (2014)
   Sense of coherence in patients with inflammatory bowel disease
   Gastroenterol Res Pract, 2014, 989038
   DOI 10.1155/2014/989038, PubMed 24527028
10. Solberg IC, Cvancarova M, Vatn MH, Moum B, IBSEN Study Group (2014)
    Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn's Disease (the IBSEN Study)
    Inflamm Bowel Dis, 20 (1), 60-8
    DOI 10.1097/01.MIB.0000436956.78220.67, PubMed 24280875

Publications 2013

1. Bager P, Befrits R, Wikman O, Lindgren S, Moum B, Hjortswang H, Dahlerup JF (2013)
   High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in Scandinavia: a longitudinal 2-year follow-up study
   Scand J Gastroenterol, 48 (11), 1286-93
   DOI 10.3109/00365521.2013.838605, PubMed 24073709
2. Bernstein CN, Ng SC, Lakatos PL, Moum B, Loftus EV, Epidemiology and Natural History Task Force of the International Organization of the Study of Inflammatory Bowel Disease (2013)
   A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease
   Inflamm Bowel Dis, 19 (9), 2001-10
   DOI 10.1097/MIB.0b013e318281f3bb, PubMed 23624887
3. Hovde Ø, Kempski-Monstad I, Småstuen MC, Solberg IC, Henriksen M, Jahnsen J, Stray N, Moum BA (2013)
   Mortality and causes of death in Crohn's disease: results from 20 years of follow-up in the IBSEN study
   Gut, 63 (5), 771-5
   DOI 10.1136/gutjnl-2013-304766, PubMed 23744613
4. Høivik ML, Reinisch W, Cvancarova M, Moum B, IBSEN study group (2013)
   Anaemia in inflammatory bowel disease: a population-based 10-year follow-up
   Aliment Pharmacol Ther, 39 (1), 69-76
   DOI 10.1111/apt.12541, PubMed 24172277
5. Jelsness-Jørgensen LP, Bernklev T, Moum B (2013)
   Calprotectin Is a Useful Tool in Distinguishing Coexisting Irritable Bowel-Like Symptoms from That of Occult Inflammation among Inflammatory Bowel Disease Patients in Remission
   Gastroenterol Res Pract, 2013, 620707
   DOI 10.1155/2013/620707, PubMed 23476638
6. Opheim R, Fagermoen MS, Bernklev T, Jelsness-Jorgensen LP, Moum B (2013)
   Fatigue interference with daily living among patients with inflammatory bowel disease
   Qual Life Res, 23 (2), 707-17
   DOI 10.1007/s11136-013-0508-4, PubMed 23975381
7. Reinisch W, Chowers Y, Danese S, Dignass A, Gomollón F, Nielsen OH, Lakatos PL, Lees CW, Lindgren S, Lukas M, Mantzaris GJ, Michetti P, Moum B, Peyrin-Biroulet L, Toruner M, van der Woude J, Weiss G, Stoevelaar H (2013)
   The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method
   Aliment Pharmacol Ther, 38 (9), 1109-18
   DOI 10.1111/apt.12493, PubMed 24099472

Publications 2012

1. Bernstein CN, Loftus EV, Ng SC, Lakatos PL, Moum B, Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) (2012)
   Hospitalisations and surgery in Crohn's disease
   Gut, 61 (4), 622-9
   DOI 10.1136/gutjnl-2011-301397, PubMed 22267595
2. Hovde Ø, Moum BA (2012)
   Epidemiology and clinical course of Crohn's disease: results from observational studies
   World J Gastroenterol, 18 (15), 1723-31
   DOI 10.3748/wjg.v18.i15.1723, PubMed 22553396
3. Høivik ML, Moum B, Solberg IC, Henriksen M, Cvancarova M, Bernklev T, IBSEN Group (2012)
   Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study
   Gut, 62 (3), 368-75
   DOI 10.1136/gutjnl-2012-302311, PubMed 22717453
4. Jelsness-Jørgensen LP, Bernklev T, Henriksen M, Torp R, Moum B (2012)
   Chronic fatigue is associated with increased disease-related worries and concerns in inflammatory bowel disease
   World J Gastroenterol, 18 (5), 445-52
   DOI 10.3748/wjg.v18.i5.445, PubMed 22346250
5. Jelsness-Jørgensen LP, Bernklev T, Henriksen M, Torp R, Moum B (2012)
   Is patient reported outcome (PRO) affected by different follow-up regimens in inflammatory bowel disease (IBD)? A one year prospective, longitudinal comparison of nurse-led versus conventional follow-up
   J Crohns Colitis, 6 (9), 887-94
   DOI 10.1016/j.crohns.2012.01.021, PubMed 22398072
6. Jelsness-Jørgensen LP, Bernklev T, Moum B (2012)
   Fatigue and disease-related worries among inflammatory bowel disease patients in remission; is it a reflection of coexisting IBS-like symptoms? A short report
   J Psychosom Res, 73 (6), 469-72
   DOI 10.1016/j.jpsychores.2012.08.009, PubMed 23148817
7. Jonasson C, Moum B, Bang C, Andersen KR, Hatlebakk JG (2012)
   Randomised clinical trial: a comparison between a GerdQ-based algorithm and an endoscopy-based approach for the diagnosis and initial treatment of GERD
   Aliment Pharmacol Ther, 35 (11), 1290-300
   DOI 10.1111/j.1365-2036.2012.05092.x, PubMed 22510027
8. Katsanos KH, Tatsioni A, Pedersen N, Shuhaibar M, Ramirez VH, Politi P, Ronnbrechts E, Pierik M, Clofent J, Beltrami M, Bodini P, Freitas J, Mouzas I, Fornaciari G, Moum B, Lakatos PL, Vermeire S, Langholz E, Odes S, Morain CO, Stockbrugger R, Munkholm P, Tsianos EV, EC-IBD Study Grp (2012)
   Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study (vol 5, pg 430, 2011)
   J. Crohns Colitis, 6 (1), 132-133
   DOI 10.1016/j.crohns.2011.11.023
9. Opheim R, Bernklev T, Fagermoen MS, Cvancarova M, Moum B (2012)
   Use of complementary and alternative medicine in patients with inflammatory bowel disease: results of a cross-sectional study in Norway
   Scand J Gastroenterol, 47 (12), 1436-47
   DOI 10.3109/00365521.2012.725092, PubMed 23003678

Publications 2011

1. Bager P, Befrits R, Wikman O, Lindgren S, Moum B, Hjortswang H, Hjollund NH, Dahlerup JF (2011)
   Fatigue in out-patients with inflammatory bowel disease is common and multifactorial
   Aliment Pharmacol Ther, 35 (1), 133-41
   DOI 10.1111/j.1365-2036.2011.04914.x, PubMed 22059387
2. Hoivik ML, Moum B, Solberg IC, Cvancarova M, Hoie O, Vatn MH, Bernklev T, IBSEN Study Group (2011)
   Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study
   Inflamm Bowel Dis, 18 (8), 1540-9
   DOI 10.1002/ibd.21863, PubMed 21936030
3. Høivik ML, Bernklev T, Solberg IC, Cvancarova M, Lygren I, Jahnsen J, Moum B, IBSEN Study Group (2011)
   Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study
   J Crohns Colitis, 6 (4), 441-53
   DOI 10.1016/j.crohns.2011.10.001, PubMed 22398064
4. Jelsness-Jørgensen LP, Bernklev T, Moum B (2011)
   Quality of life in patients with inflammatory bowel disease: translation, validity, reliability and sensitivity to change of the Norwegian version of the short health scale (SHS)
   Qual Life Res, 21 (9), 1671-6
   DOI 10.1007/s11136-011-0081-7, PubMed 22146840
5. Jelsness-Jørgensen LP, Moum B, Bernklev T (2011)
   Worries and Concerns among Inflammatory Bowel Disease Patients Followed Prospectively over One Year
   Gastroenterol Res Pract, 2011, 492034
   DOI 10.1155/2011/492034, PubMed 21912537
6. Jelsness-Jørgensen LP, Ribu L, Bernklev T, Moum BA (2011)
   Measuring health-related quality of life in non-complicated diabetes patients may be an effective parameter to assess patients at risk of a more serious disease course: a cross-sectional study of two diabetes outpatient groups
   J Clin Nurs, 20 (9-10), 1255-63
   DOI 10.1111/j.1365-2702.2010.03554.x, PubMed 21401763
7. Katsanos KH, Tatsioni A, Pedersen N, Shuhaibar M, Ramirez VH, Politi P, Rombrechts E, Pierik M, Clofent J, Beltrami M, Bodini P, Freitas J, Mouzas I, Fornaciari G, Moum B, Lakatos PL, Vermeire S, Langholz E, Odes S, Morain CO, Stockbrügger R, Munkholm P, Tsianos EV (2011)
   Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study
   J Crohns Colitis, 5 (5), 430-42
   DOI 10.1016/j.crohns.2011.04.013, PubMed 21939917
8. Opheim R, Hoivik ML, Solberg IC, Moum B, IBSEN Study Group (2011)
   Complementary and alternative medicine in patients with inflammatory bowel disease: the results of a population-based inception cohort study (IBSEN)
   J Crohns Colitis, 6 (3), 345-53
   DOI 10.1016/j.crohns.2011.09.007, PubMed 22405172

Publications 2010

1. Bager P, Befrits R, Wikman O, Lindgren S, Moum B, Hjortswang H, Dahlerup JF (2010)
   The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia
   Scand J Gastroenterol, 46 (3), 304-9
   DOI 10.3109/00365521.2010.533382, PubMed 21073374
2. Bengtson MB, Solberg IC, Aamodt G, Jahnsen J, Moum B, Vatn MH, IBSEN Study Group (2010)
   Relationships between inflammatory bowel disease and perinatal factors: both maternal and paternal disease are related to preterm birth of offspring
   Inflamm Bowel Dis, 16 (5), 847-55
   DOI 10.1002/ibd.21120, PubMed 19795509
3. Hatlebakk JG, Lerang F, Moum B (2010)
   [Proton pump inhibitors do not cause stomach cancer]
   Tidsskr Nor Laegeforen, 130 (6), 592
   DOI 10.4045/tidsskr.10.0084, PubMed 20348996
4. Moum B, Jahnsen J (2010)
   [Obesity surgery in inflammatory bowel disease]
   Tidsskr Nor Laegeforen, 130 (6), 638-9
   DOI 10.4045/tidsskr.09.1281, PubMed 20349013
5. Moum B, Jahnsen J, Bernklev T (2010)
   Fecal calprotectin variability in Crohn's disease
   Inflamm Bowel Dis, 16 (7), 1091-2
   DOI 10.1002/ibd.21136, PubMed 19834972

Publications 2009

1. Bengtson MB, Solberg C, Aamodt G, Jahnsen J, Moum B, Sauar J, Vatn MH, Ibsen Study Group (2009)
   Clustering in time of familial IBD separates ulcerative colitis from Crohn's disease
   Inflamm Bowel Dis, 15 (12), 1867-74
   DOI 10.1002/ibd.20978, PubMed 19434721
2. Odes S, Vardi H, Friger M, Esser D, Wolters F, Moum B, Waters H, Elkjaer M, Bernklev T, Tsianos E, O'Morain C, Stockbrügger R, Munkholm P, Langholz E (2009)
   Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis
   Aliment Pharmacol Ther, 31 (7), 735-44
   DOI 10.1111/j.1365-2036.2009.04228.x, PubMed 20047578
3. Solberg IC, Lygren I, Cvancarova M, Jahnsen J, Stray N, Sauar J, Schreiber S, Moum B, Vatn MH, IBSEN Study Group (2009)
   Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease
   Inflamm Bowel Dis, 15 (3), 406-14
   DOI 10.1002/ibd.20781, PubMed 19009607
4. Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, Bernklev T, Henriksen M, Sauar J, Vatn MH, Moum B, IBSEN Study Group (2009)
   Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)
   Scand J Gastroenterol, 44 (4), 431-40
   DOI 10.1080/00365520802600961, PubMed 19101844
5. Øresland T, Moum B (2009)
   [Surgery, inflammatory bowel disease and biological treatment]
   Tidsskr Nor Laegeforen, 129 (22), 2389-90
   DOI 10.4045/tidsskr.09.1231, PubMed 19935950

Publications 2008

1. Bengtson MB, Solberg C, Aamodt G, Sauar J, Jahnsen J, Moum B, Lygren I, Vatn MH, IBSEN study group (2008)
   Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years
   J Crohns Colitis, 3 (2), 92-9
   DOI 10.1016/j.crohns.2008.11.002, PubMed 21172251
2. Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B, IBSEN Study Group (2008)
   C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study
   Gut, 57 (11), 1518-23
   DOI 10.1136/gut.2007.146357, PubMed 18566104
3. Hoie O, Moum B (2008)
   Appendectomy and inflammatory bowel disease: The end of a dogma? Reply
   Am. J. Gastroenterol., 103 (2), 492
   DOI 10.1111/j.1572-0241.2007.01646_12.x
4. Moum B (2008)
   Which are the 5-ASA compound side effects and how is it possible to avoid them?
   Inflamm Bowel Dis, 14 Suppl 2, S212-3
   DOI 10.1002/ibd.20712, PubMed 18816767
5. Aamodt G, Bukholm G, Jahnsen J, Moum B, Vatn MH, IBSEN Study Group (2008)
   The association between water supply and inflammatory bowel disease based on a 1990-1993 cohort study in southeastern Norway
   Am J Epidemiol, 168 (9), 1065-72
   DOI 10.1093/aje/kwn218, PubMed 18801890
6. Aamodt G, Jahnsen J, Bengtson MB, Moum B, Vatn MH, IBSEN Study Group (2008)
   Geographic distribution and ecological studies of inflammatory bowel disease in southeastern Norway in 1990-1993
   Inflamm Bowel Dis, 14 (7), 984-91
   DOI 10.1002/ibd.20417, PubMed 18338775

Publications 2007

1. Henriksen M, Jahnsen J, Lygren I, Vatn MH, Moum B, IBSEN Study Group (2007)
   Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study
   Am J Gastroenterol, 102 (9), 1955-63
   DOI 10.1111/j.1572-0241.2007.01368.x, PubMed 17573793
2. Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, Moum B, Ibsen Study Group (2007)
   Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study)
   Scand J Gastroenterol, 42 (5), 602-10
   DOI 10.1080/00365520601076124, PubMed 17454881
3. Henriksen M, Moum B (2007)
   [Colorectal cancer in inflammatory bowel disease]
   Tidsskr Nor Laegeforen, 127 (20), 2696-9
   PubMed 17952155
4. Höie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, Odes S, Mouzas IA, Beltrami M, Langholz E, Stockbrügger R, Vatn M, Moum B, European Collaborative Study Group of Inflammatory Bowel Disease (EC-IBD) (2007)
   Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort
   Am J Gastroenterol, 102 (8), 1692-701
   DOI 10.1111/j.1572-0241.2007.01265.x, PubMed 17555460
5. Høie O, Aamodt G, Vermeire S, Bernklev T, Odes S, Wolters FL, Riis L, Politi P, Tsianos EV, Butrón M, Stockbrügger RW, Munkholm P, Vatn M, Moum B, European Collaborative study group of Inflammatory Bowel Disease (EC-IBD) (2007)
   Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years
   J Crohns Colitis, 2 (2), 114-22
   DOI 10.1016/j.crohns.2007.10.001, PubMed 21172201
6. Katsanos KH, Vermeire S, Christodoulou DK, Riis L, Wolters F, Odes S, Freitas J, Hoie O, Beltrami M, Fornaciari G, Clofent J, Bodini P, Vatn M, Nunes PB, Moum B, Munkholm P, Limonard C, Stockbrugger R, Rutgeerts P, Tsianos EV, EC-IBD Study Group (2007)
   Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study
   Digestion, 75 (2-3), 113-21
   DOI 10.1159/000104731, PubMed 17598963
7. Moum B (2007)
   [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?]
   Tidsskr Nor Laegeforen, 127 (12), 1673
   PubMed 17571118
8. Moum B (2007)
   [Follow up of the use of biological drugs against inflammatory bowel diseases]
   Tidsskr Nor Laegeforen, 127 (21), 2841-2
   PubMed 17987080
9. Moum B, Konopski Z, Tufteland KF, Jahnsen J (2007)
   Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab
   Inflamm Bowel Dis, 13 (12), 1584-6
   DOI 10.1002/ibd.20230, PubMed 17663423
10. Odes S, Friger M, Vardi H, Claessens G, Bossuyt X, Riis L, Munkholm P, Wolters F, Yona H, Hoie O, Beltrami M, Tsianos E, Katsanos K, Mouzas I, Clofent J, Monteiro E, Messori A, Politi P, O'Morain C, Limonard C, Russel M, Vatn M, Moum B, Stockbrugger R, Vermeire S et al. (2007)
    Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: a project of the European Collaborative Study Group on Inflammatory Bowel Disease
    Inflamm Bowel Dis, 13 (7), 874-81
    DOI 10.1002/ibd.20122, PubMed 17278126
11. Odes S, Vardi H, Friger M, Wolters F, Hoie O, Moum B, Bernklev T, Yona H, Russel M, Munkholm P, Langholz E, Riis L, Politi P, Bondini P, Tsianos E, Katsanos K, Clofent J, Vermeire S, Freitas J, Mouzas I, Limonard C, O'Morain C, Monteiro E, Fornaciari G, Vatn M et al. (2007)
    Effect of phenotype on health care costs in Crohn's disease: A European study using the Montreal classification
    J Crohns Colitis, 1 (2), 87-96
    DOI 10.1016/j.crohns.2007.08.004, PubMed 21172190
12. Riis L, Vind I, Vermeire S, Wolters F, Katsanos K, Politi P, Freitas J, Mouzas IA, O'Morain C, Ruiz-Ochoa V, Odes S, Binder V, Munkholm P, Moum B, Stockbrügger R, Langholz E, European Collaborative Study Group on Inflammatory Bowel Disease (2007)
    The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients
    Inflamm Bowel Dis, 13 (1), 24-32
    DOI 10.1002/ibd.20047, PubMed 17206636
13. Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J, Moum B, Lygren I, IBSEN Study Group (2007)
    Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study
    Clin Gastroenterol Hepatol, 5 (12), 1430-8
    DOI 10.1016/j.cgh.2007.09.002, PubMed 18054751
14. Wolters FL, Joling C, Russel MG, Sijbrandij J, De Bruin M, Odes S, Riis L, Munkholm P, Bodini P, Ryan B, O'Morain C, Mouzas IA, Tsianos E, Vermeire S, Monteiro E, Limonard C, Vatn M, Fornaciari G, Rodriguez D, Groot W, Moum B, Stockbrügger RW, European Collaborative Study Group On Inflammatory Bowel Disease (EC-IBD) (2007)
    Treatment inferred disease severity in Crohn's disease: evidence for a European gradient of disease course
    Scand J Gastroenterol, 42 (3), 333-44
    DOI 10.1080/00365520600930750, PubMed 17354113

Publications 2006

1. Bernklev T, Jahnsen J, Henriksen M, Lygren I, Aadland E, Sauar J, Schulz T, Stray N, Vatn M, Moum B (2006)
   Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease
   Inflamm Bowel Dis, 12 (5), 402-12
   DOI 10.1097/01.MIB.0000218762.61217.4a, PubMed 16670530
2. Hansen AN, Bergheim R, Fagertun H, Lund H, Wiklund I, Moum B (2006)
   Long-term management of patients with symptoms of gastro-oesophageal reflux disease -- a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting
   Int J Clin Pract, 60 (1), 15-22
   DOI 10.1111/j.1368-5031.2006.00768.x, PubMed 16409423
3. Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold Ø, Schulz T, Vatn MH, Moum B, IBSEN Study Group (2006)
   Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study)
   Inflamm Bowel Dis, 12 (7), 543-50
   DOI 10.1097/01.MIB.0000225339.91484.fc, PubMed 16804390
4. Henriksen M, Jahnsen J, Lygren I, Sauar J, Schulz T, Stray N, Vatn MH, Moum B, Ibsen Study Group (2006)
   Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study)
   Scand J Gastroenterol, 41 (9), 1037-43
   DOI 10.1080/00365520600554527, PubMed 16938716
5. Hoie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, Tsianos E, Beltrami M, Odes S, Munkholm P, Vatn M, Stockbrügger RW, Moum B, European Collaborative Study Group of Inflammatory Bowel Disease (2006)
   Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years
   Gastroenterology, 132 (2), 507-15
   DOI 10.1053/j.gastro.2006.11.015, PubMed 17258717
6. Höie O, Schouten LJ, Wolters FL, Solberg IC, Riis L, Mouzas IA, Politi P, Odes S, Langholz E, Vatn M, Stockbrügger RW, Moum B, European Collaborative Study Group of Inflammatory Bowel Disease (EC-IBD) (2006)
   Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis
   Gut, 56 (4), 497-503
   DOI 10.1136/gut.2006.101519, PubMed 17028127
7. Medici V, Mascheretti S, Croucher PJ, Stoll M, Hampe J, Grebe J, Sturniolo GC, Solberg C, Jahnsen J, Moum B, Schreiber S, Vatn MH (2006)
   Extreme heterogeneity in CARD15 and DLG5 Crohn disease-associated polymorphisms between German and Norwegian populations
   Eur J Hum Genet, 14 (4), 459-68
   DOI 10.1038/sj.ejhg.5201576, PubMed 16493449
8. Odes S, Vardi H, Friger M, Wolters F, Russel MG, Riis L, Munkholm P, Politi P, Tsianos E, Clofent J, Vermeire S, Monteiro E, Mouzas I, Fornaciari G, Sijbrandij J, Limonard C, Van Zeijl G, O'morain C, Moum B, Vatn M, Stockbrugger R, European Collaborative Study on Inflammatory Bowel Disease (2006)
   Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation
   Gastroenterology, 131 (3), 719-28
   DOI 10.1053/j.gastro.2006.05.052, PubMed 16952541
9. Odes S, Vardi H, Friger M, Wolters F, Russel MG, Riis L, Munkholm P, Politi P, Tsianos E, Clofent J, Vermeire S, Monteiro E, Mouzas I, Fornaciari G, Sijbrandij J, Limonard C, Van ZG, O'Morain C, Moum B, Vatn M, Stockbrugger R (2006)
   Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. (vol 131, pg 719, 2006)
   Gastroenterology, 131 (6), 2029
10. Riis L, Vind I, Politi P, Wolters F, Vermeire S, Tsianos E, Freitas J, Mouzas I, Ruiz Ochoa V, O'Morain C, Odes S, Binder V, Moum B, Stockbrügger R, Langholz E, Munkholm P, European Collaborative study group on Inflammatory Bowel Disease (2006)
    Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease
    Am J Gastroenterol, 101 (7), 1539-45
    DOI 10.1111/j.1572-0241.2006.00602.x, PubMed 16863558
11. Tangen M, Andresen SJ, Moum B, Hauge T (2006)
    [Stent insertion as palliation of cancer in the esophagus and cardia]
    Tidsskr Nor Laegeforen, 126 (12), 1607-9
    PubMed 16770371
12. Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, Munkholm P, Langholz E, Bodini P, O'Morain C, Katsanos K, Tsianos E, Vermeire S, Van Zeijl G, Limonard C, Hoie O, Vatn M, Moum B, Stockbrügger RW, European Collaborative Study Group On Inflammatory Bowel Disease (2006)
    Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study
    Scand J Gastroenterol Suppl (243), 46-54
    DOI 10.1080/00365520600664250, PubMed 16782622

Publications 2005

1. Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B (2005)
   Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms
   Inflamm Bowel Dis, 11 (10), 909-18
   DOI 10.1097/01.mib.0000179467.01748.99, PubMed 16189421
2. Bernklev T, Jahnsen J, Schulz T, Sauar J, Lygren I, Henriksen M, Stray N, Kjellevold Ø, Aadland E, Vatn M, Moum B (2005)
   Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis
   Eur J Gastroenterol Hepatol, 17 (10), 1037-45
   DOI 10.1097/00042737-200510000-00006, PubMed 16148548
3. Hansen AN, Wahlqvist P, Jørgensen E, Bergheim R, Fagertun H, Lund H, Moum B (2005)
   Six-month management of patients following treatment for gastroesophageal reflux disease symptoms -- a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting
   Int J Clin Pract, 59 (6), 655-64
   DOI 10.1111/j.1368-5031.2005.00563.x, PubMed 15924593
4. Norman Hansen A, Bergheim R, Fagertun H, Lund H, Moum B (2005)
   A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease
   Int J Clin Pract, 59 (6), 665-71
   DOI 10.1111/j.1368-5031.2005.00564.x, PubMed 15924594
5. Palm Ø, Bernklev T, Moum B, Gran JT (2005)
   Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life
   J Rheumatol, 32 (9), 1755-9
   PubMed 16142874
6. Wolters FL, Russel MG, Sijbrandij J, Ambergen T, Odes S, Riis L, Langholz E, Politi P, Qasim A, Koutroubakis I, Tsianos E, Vermeire S, Freitas J, van Zeijl G, Hoie O, Bernklev T, Beltrami M, Rodriguez D, Stockbrügger RW, Moum B (2005)
   Phenotype at diagnosis predicts recurrence rates in Crohn's disease
   Gut, 55 (8), 1124-30
   DOI 10.1136/gut.2005.084061, PubMed 16361306
7. Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, Munkholm P, Bodini P, O'Morain C, Mouzas IA, Tsianos E, Vermeire S, Monteiro E, Limonard C, Vatn M, Fornaciari G, Pereira S, Moum B, Stockbrügger RW, European Collaborative study group on Inflammatory Bowel Disease (EC-IBD) (2005)
   Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort
   Gut, 55 (4), 510-8
   DOI 10.1136/gut.2005.072793, PubMed 16150857

Publications 2004

1. Armstrong D, Talley NJ, Lauritsen K, Moum B, Lind T, Tunturi-Hihnala H, Venables T, Green J, Bigard MA, Mössner J, Junghard O (2004)
   The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole
   Aliment Pharmacol Ther, 20 (4), 413-21
   DOI 10.1111/j.1365-2036.2004.02085.x, PubMed 15298635
2. Bernklev T, Jahnsen J, Aadland E, Sauar J, Schulz T, Lygren I, Henriksen M, Stray N, Kjellevold O, Vatn M, Moum B, IBSEN Study Group (2004)
   Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis
   Scand J Gastroenterol, 39 (4), 365-73
   DOI 10.1080/00365520310008386, PubMed 15125469
3. Størdal K, Jahnsen J, Bentsen BS, Moum B (2004)
   Pediatric inflammatory bowel disease in southeastern Norway: a five-year follow-up study
   Digestion, 70 (4), 226-30
   DOI 10.1159/000082893, PubMed 15627770

Publications 2002

1. Bentsen BS, Moum B, Ekbom A (2002)
   Incidence of inflammatory bowel disease in children in southeastern Norway: a prospective population-based study 1990-94
   Scand J Gastroenterol, 37 (5), 540-5
   DOI 10.1080/00365520252903080, PubMed 12059055
2. Bernklev T, Moum B, Moum T, Inflammatory Bowel South-Eastern Norway (IBSEN) Group of Gastroenterologists (2002)
   Quality of life in patients with inflammatory bowel disease: translation, data quality, scaling assumptions, validity, reliability and sensitivity to change of the Norwegian version of IBDQ
   Scand J Gastroenterol, 37 (10), 1164-74
   DOI 10.1080/003655202760373371, PubMed 12408521
3. Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, Jahnsen J, Moum B, Klump B, Krawczak M, Mirza MM, Foelsch UR, Vatn M, Schreiber S (2002)
   Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study
   Lancet, 359 (9318), 1661-5
   DOI 10.1016/S0140-6736(02)08590-2, PubMed 12020527
4. Johnsson F, Moum B, Vilien M, Grove O, Simren M, Thoring M (2002)
   On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole
   Scand J Gastroenterol, 37 (6), 642-7
   DOI 10.1080/00365520212499, PubMed 12126240
5. Palm O, Moum B, Ongre A, Gran JT (2002)
   Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study)
   J Rheumatol, 29 (3), 511-5
   PubMed 11908564
6. Palm Ø, Moum B, Gran JT (2002)
   Estimation of Sjögren's syndrome among IBD patients. A six year post-diagnostic prevalence study
   Scand J Rheumatol, 31 (3), 140-5
   PubMed 12195627

Publications 2001

1. Moum B (2001)
   [Incontinence following emergency surgery and ileoanal anastomosis in ulcerative colitis]
   Tidsskr Nor Laegeforen, 121 (11), 1415
   PubMed 11419116
2. Palm O, Moum B, Jahnsen J, Gran JT (2001)
   Fibromyalgia and chronic widespread pain in patients with inflammatory bowel disease: a cross sectional population survey
   J Rheumatol, 28 (3), 590-4
   PubMed 11296964
3. Palm Ø, Moum B, Jahnsen J, Gran JT (2001)
   The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study)
   Rheumatology (Oxford), 40 (11), 1256-61
   DOI 10.1093/rheumatology/40.11.1256, PubMed 11709609
4. Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, Schulz T, Omland TM, Delle M, Junghard O (2001)
   Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months
   Aliment Pharmacol Ther, 15 (3), 347-54
   DOI 10.1046/j.1365-2036.2001.00943.x, PubMed 11207509
5. van der Eijk I, Sixma H, Smeets T, Veloso FT, Odes S, Montague S, Fornaciari G, Moum B, Stockbrügger R, Russel M, European Collaborative Study Group on IBD (2001)
   Quality of health care in inflammatory bowel disease: development of a reliable questionnaire (QUOTE-IBD) and first results
   Am J Gastroenterol, 96 (12), 3329-36
   DOI 10.1111/j.1572-0241.2001.05334.x, PubMed 11774945

Publications 2000

1. Størdal K, Bentsen B, Skulstad H, Moum B (2000)
   [Reflux disease and 24-hour esophageal pH monitoring in children]
   Tidsskr Nor Laegeforen, 120 (2), 183-6
   PubMed 10851912

Publications 1998

1. Lerang F, Haug JB, Moum B, Mowinckel P, Berge T, Ragnhildstveit E, Bjørneklett A (1998)
   Accuracy of IgG serology and other tests in confirming Helicobacter pylori eradication
   Scand J Gastroenterol, 33 (7), 710-5
   DOI 10.1080/00365529850171648, PubMed 9712234
2. Lerang F, Moum B, Mowinckel P, Haug JB, Ragnhildstveit E, Berge T, Bjørneklett A (1998)
   Accuracy of seven different tests for the diagnosis of Helicobacter pylori infection and the impact of H2-receptor antagonists on test results
   Scand J Gastroenterol, 33 (4), 364-9
   DOI 10.1080/00365529850170982, PubMed 9605257
3. Lerang F, Moum B, Ragnhildstveit E, Sandvei PK, Tolås P, Whist JE, Henriksen M, Haug JB, Berge T (1998)
   Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance
   Am J Gastroenterol, 93 (2), 212-6
   DOI 10.1111/j.1572-0241.1998.00212.x, PubMed 9468244

Publications 1997

1. Lerang F, Moum B, Haug JB, Berge T, Tolås P, Sandvei PK, Torp R, Tønnesen T (1997)
   Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy
   Scand J Gastroenterol, 32 (12), 1209-14
   DOI 10.3109/00365529709028149, PubMed 9438318
2. Lerang F, Moum B, Haug JB, Tolås P, Breder O, Aubert E, Høie O, Søberg T, Flaaten B, Farup P, Berge T (1997)
   Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?
   Am J Gastroenterol, 92 (2), 248-53
   PubMed 9040200
3. Moum B (1997)
   [Should every patient with ulcerative colitis/Crohn disease be vaccinated against pneumococcal infection?]
   Tidsskr Nor Laegeforen, 117 (22), 3262-3
   PubMed 9411871
4. Skulstad H, Jacobsen MB, Moum B, Odegaard A (1997)
   [Gastrointestinal amyloidosis. Differential diagnosis or a complication of inflammatory bowel disease?]
   Tidsskr Nor Laegeforen, 117 (24), 3489-91
   PubMed 9411905

Publications 1995

1. VATN MH, MOUM B (1995)
   IBD in Norway, with special emphasis on the incidence study of southeastern Norway from 1990, initiated in collaboration with the European Community IBD study group
   FALK SYMP, 76, 30-36

Publications 1994

1. Lerang F, Moum B, Ragnhildstveit E (1994)
   [Alternative treatment of Helicobacter pylori infections]
   Tidsskr Nor Laegeforen, 114 (12), 1465
   PubMed 8079238

Publications 1992

1. Moum B, Aukrust P, Schrumpf E, Mørk T, Mathisen O, Elgjo K (1992)
   [Natural products can be hazardous to health]
   Tidsskr Nor Laegeforen, 112 (10), 1308-11
   PubMed 1579916

Publications 1991

1. Aukrust P, Frøland SS, Kvale D, Egge K, Farstad IN, Holter E, Moum B (1991)
   [Symptomatic cytomegalovirus infection in patients with acquired immunodeficiency syndrome]
   Tidsskr Nor Laegeforen, 111 (28), 3379-84
   PubMed 1665253
2. Aukrust P, Moum B, Farstad IN, Holter E, Bjørneklett A, Kremer D (1991)
   Fatal cytomegalovirus (CMV) colitis in a patient receiving low dose prednisolone therapy
   Scand J Infect Dis, 23 (4), 495-9
   DOI 10.3109/00365549109075099, PubMed 1659739
3. Moum B, Aukrust P, Bjørneklett A, Frøland SS, Farstad IN, Holter E (1991)
   [Cytomegalovirus disease in the gastrointestinal tract]
   Tidsskr Nor Laegeforen, 111 (28), 3388-91
   PubMed 1665255
4. Moum B, Aukrust P, Fausa O, Farstad IN, Holter E (1991)
   [Cytomegalovirus disease in the upper gastrointestinal tract. Endoscopic findings]
   Tidsskr Nor Laegeforen, 111 (28), 3391-3
   PubMed 1665256

Publications 1984

1. Moum B (1984)
   [Erroneous dosage, overdosage and adverse effects following digoxin administration]
   Tidsskr Nor Laegeforen, 104 (24), 1663-4
   PubMed 6474444